Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

Delayed Quote. Delayed  - 07/22 10:01:09 pm
46.32 USD   +0.48%
07/21BAXTER INTERNAT : half-yearly earnings release
07/19 BAXTER : Declares Quarterly Dividend
06/29 BAXTER : Announces Health Canada Approval of AMIA Automated Peritone..
News SummaryMost relevantAll newsSector news 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
07/21BAXTER INTERNATIONAL INC : half-yearly earnings release
07/19 BAXTER : Declares Quarterly Dividend
07/07 BAXTER : Announces Health Canada Approval of AMIA Automated Peritoneal Dialysis ..
06/30 BAXTER : New Baxter Study Demonstrates Perceived Value of Telemedicine to Increa..
06/29 BAXTER : Announces Health Canada Approval of AMIA Automated Peritoneal Dialysis ..
06/28 BAXTER : Recognized as One of the Most Community-Minded Companies in the United ..
06/27 BAXTER INTERNATIONAL : Second Quarter 2016 Financial Results
06/23 BAXTER : Patent Issued for Compositions and Methods for Drug Delivery (USPTO 936..
06/23 BAXTER INTERNATIONAL INC : Material Modification to Rights of Security Holders, ..
06/23 BAXTER : New Baxter Study Demonstrates Perceived Value of Telemedicine to Increa..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
07/22DJDEXCOM : Shares Rise After FDA Panel Vote
07/21DJSTRYKER : Raises Annual Guidance, but Current Quarter's View Misses Targets
07/20DJSt. Jude Medical Logs Double-Digit Sales Growth -- Update
07/20DJAbbott Labs Profit Tops Views
07/20DJABBOTT LABORATORIES : Labs Profit Tops Views
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
07/20 ELI LILLY : Executive Compensation And Other Metrics
07/19 Baxter declares $0.13 dividend
07/14 Fundamentals That Will Impact All Our Portfolios, Domestic And Internationall..
07/05 The Dividend Growth 50 Trumps The Market By Nearly 300%
07/05 POWERSHARES S&P 500 HIGH DIVIDEND LO : Standard Deviation Strategy
Financials ($)
Sales 2016 10 087 M
EBIT 2016 1 171 M
Net income 2016 1 899 M
Debt 2016 680 M
Yield 2016 0,88%
P/E ratio 2016 9,25
P/E ratio 2017 27,26
EV / Sales 2016 2,60x
EV / Sales 2017 2,50x
Capitalization 25 581 M
More Financials
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 14
Average target price 48,8 $
Spread / Average Target 5,3%
Consensus details
EPS Revisions
More Estimates Revisions
José E. Almeida Chairman, President & Chief Executive Officer
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
John D. Forsyth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC13.23%121 481
C R BARD INC21.41%16 863
TERUMO CORP25.74%16 678
More Results